Key Points
- Annie Yoshiyama, SVP of Allogene Therapeutics, sold 9,586 shares on April 21 at an average price of $2.31 (totaling $22,143.66) to cover tax withholding on vested awards, reducing her stake by 7.15% to 124,517 shares valued at about $287,634.
- Wall Street sentiment is generally positive with a consensus rating of “Moderate Buy” and an average price target of $8.44, following multiple recent upgrades and higher price targets from firms including UBS, Robert W. Baird, Truist and JPMorgan.
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Annie Yoshiyama sold 9,586 shares of the stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an average price of $2.31, for a total value of $22,143.66. Following the sale, the senior vice president directly owned 124,517 shares of the company's stock, valued at $287,634.27. The trade was a 7.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Annie Yoshiyama also recently made the following trade(s):
- On Monday, February 2nd, Annie Yoshiyama sold 4,167 shares of Allogene Therapeutics stock. The stock was sold at an average price of $1.72, for a total value of $7,167.24.
Allogene Therapeutics Trading Down 1.7%
ALLO stock opened at $2.35 on Friday. The stock has a market cap of $575.33 million, a P/E ratio of -2.70 and a beta of 0.53. The stock's fifty day simple moving average is $2.40 and its two-hundred day simple moving average is $1.76. Allogene Therapeutics, Inc. has a 1-year low of $0.86 and a 1-year high of $4.46.
Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last announced its earnings results on Thursday, March 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.08. As a group, analysts forecast that Allogene Therapeutics, Inc. will post -0.73 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have commented on the stock. JPMorgan Chase & Co. raised shares of Allogene Therapeutics from an "underweight" rating to a "neutral" rating in a research report on Thursday, April 16th. Truist Financial upgraded shares of Allogene Therapeutics to a "strong-buy" rating in a research note on Wednesday, March 25th. UBS Group started coverage on shares of Allogene Therapeutics in a report on Wednesday, January 7th. They issued a "buy" rating and a $8.00 price target on the stock. Robert W. Baird upped their price objective on Allogene Therapeutics from $7.00 to $9.00 and gave the company an "outperform" rating in a research note on Tuesday, April 14th. Finally, Citizens Jmp increased their price objective on Allogene Therapeutics from $5.00 to $8.00 and gave the company a "market outperform" rating in a report on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Allogene Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $8.44.
View Our Latest Stock Report on Allogene Therapeutics
Hedge Funds Weigh In On Allogene Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Savant Capital LLC bought a new position in Allogene Therapeutics during the third quarter worth about $27,000. Kestra Private Wealth Services LLC bought a new stake in shares of Allogene Therapeutics in the first quarter valued at approximately $27,000. Russell Investments Group Ltd. lifted its stake in shares of Allogene Therapeutics by 11,159.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 21,844 shares of the company's stock valued at $27,000 after buying an additional 21,650 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of Allogene Therapeutics by 5,267.6% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 24,047 shares of the company's stock valued at $30,000 after buying an additional 23,599 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV bought a new position in Allogene Therapeutics in the 3rd quarter worth approximately $30,000. Institutional investors own 83.63% of the company's stock.
About Allogene Therapeutics
(
Get Free Report)
Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.
The company's pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
